<img alt="Galen Growth News" data-logo-alt="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" data-src="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" class="logoimg logo-dark lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img alt="Galen Growth News" data-logo-alt="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" data-src="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" class="logoimg logo-dark lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img src="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" class="logoimg logo-dark" alt="Galen Growth News" data-logo-alt="https://news.galengrowth.com/wp-content/uploads/2020/03/Galen-Growth-News.png" />

TrialScope

3D Render of COVID-19 Vaccine

TrialScope Supports Moderna for Diversity Enrollment in Moderna’s Phase 3 Study of its COVID-19 Vaccine

© 2023 Galen Growth Asia Pte Ltd. All Rights Reserved.